What is the recommended treatment algorithm for psoriasis considering disease severity, joint involvement, and comorbid conditions?

Treatment of Psoriasis

For mild psoriasis (<3% body surface area), start with topical corticosteroids combined with vitamin D analogs; for moderate-to-severe disease (≥3% BSA or high-impact sites), initiate biologic therapy—specifically TNF inhibitors or IL-17/IL-23 inhibitors—as first-line systemic treatment, with mandatory screening for psoriatic arthritis and cardiovascular comorbidities at every visit. 1, 2, 3

Disease Severity Classification

Body surface area (BSA) determines initial treatment pathway:

• Mild: <3% BSA affected 1, 2
• Moderate: 3-10% BSA affected 1, 2
• Severe: ≥10% BSA affected 1, 2

Critical caveat: Disease is considered severe regardless of BSA when involving high-impact sites (face, genitals, hands, feet, scalp, intertriginous areas), causing major emotional distress, or producing intractable pruritus. 1, 2

Treatment Algorithm by Severity

Mild Psoriasis (<3% BSA)

First-line topical therapy:

• Topical corticosteroids (potency matched to body site) 4, 3, 5
• Vitamin D analogs (calcipotriene) 4, 3, 5
• Combination corticosteroid/vitamin D analog products provide superior efficacy 3, 5
• Calcineurin inhibitors for facial and intertriginous involvement 3
• Keratolytics for thick plaques 3

Moderate-to-Severe Psoriasis (≥3% BSA)

Biologic therapy is recommended as first-line systemic treatment due to superior efficacy and acceptable safety profiles: 3

Biologic options in order of mechanism:

• TNF-α inhibitors: etanercept, adalimumab, certolizumab, infliximab 3, 5
• IL-17 inhibitors: secukinumab, ixekizumab, bimekizumab, brodalumab 3, 5
• IL-12/23 (p40) inhibitor: ustekinumab 3, 5
• IL-23 (p19) inhibitors: guselkumab, tildrakizumab, risankizumab, mirikizumab 3, 5

Alternative systemic options when biologics are contraindicated:

• Methotrexate 6, 3, 5
• Cyclosporine 5
• Acitretin 3, 5
• Apremilast (phosphodiesterase-4 inhibitor) 3, 5

Phototherapy:

• Narrowband UV-B is the most commonly prescribed light therapy 3, 5
• PUVA (psoralen plus UV-A) as alternative 5

Mandatory Screening for Comorbidities

Psoriatic Arthritis Screening (Every Visit)

All patients with cutaneous psoriasis must be screened for psoriatic arthritis: 6

• Prevalence: 30-33% of psoriasis patients develop psoriatic arthritis 6
• Timing: Skin lesions precede arthritis in 72.7% of cases; arthritis precedes skin in 14.9%; simultaneous onset in remaining cases 6
• Peak onset: 10-11 years after skin disease diagnosis 6

Key symptoms to assess:

• Morning joint stiffness 6
• Joint swelling, redness, warmth 6
• Enthesitis (tendon/ligament insertion point pain) 6
• Dactylitis ("sausage digits") 6

Action required: Patients with signs/symptoms suspicious for psoriatic arthritis should be fully evaluated and either treated if diagnosis is clear or referred to rheumatology immediately to prevent permanent joint destruction. 6

Cardiovascular Risk Assessment

Psoriasis is a systemic inflammatory disease with increased cardiovascular morbidity and mortality: 6, 1

Screen for metabolic syndrome components:

• Obesity 6
• Hypertension 6
• Dyslipidemia 6
• Type 2 diabetes 6

Cardiovascular risk data:

• Severe psoriasis increases myocardial infarction risk (HR 5.13 per 1000 person-years vs 3.58 in controls) 6
• Risk is age-dependent, with younger patients having highest relative risk 6
• Psoriatic arthritis further increases cardiovascular event risk (HR 1.63) 6

Critical treatment consideration: TNF inhibitors reduce major cardiovascular event risk by 50% (HR 0.50) compared to topical agents, and by 45% compared to methotrexate (HR 0.55). 6

Additional Comorbidity Screening

• Depression and psychological distress 7, 3
• Lymphoma risk 4, 7
• Non-alcoholic fatty liver disease 8, 7
• Inflammatory bowel disease 3

Treatment Selection Based on Comorbidities

Patients with Psoriatic Arthritis

Biologics effective for both skin and joints:

• TNF-α inhibitors (etanercept, adalimumab, certolizumab, infliximab) 6, 3
• IL-17 inhibitors 3
• IL-12/23 inhibitor (ustekinumab) 3

Etanercept specifically recommended for psoriatic arthritis, nail psoriasis, pustular, and erythrodermic variants. 1

Patients with Cardiovascular Comorbidities

Preferred systemic agents:

• TNF inhibitors provide cardiovascular protection (50% reduction in major cardiovascular events) 6
• Statins should be co-prescribed (69% reduction in cardiovascular events, HR 0.31) 6

Avoid or use with extreme caution:

• Systemic corticosteroids may trigger skin flares, though low-dose (≤7.5 mg/day) may be used cautiously 6
• β-blockers can exacerbate psoriasis 1

Patients with Metabolic Syndrome

Non-pharmacological interventions are essential adjuncts:

• Weight loss through dietary modification 8
• Smoking cessation 8
• Regular physical exercise 8

These lifestyle modifications improve treatment response and reduce cardiovascular risk. 8

Special Considerations

Guttate Psoriasis

Clinical presentation: 1-10 mm salmon-pink papules with fine scale, typically on trunk and proximal extremities, most common in patients <30 years old. 1, 9

Trigger identification: Search for streptococcal infection via throat culture or anti-streptolysin O serology. 9

Drug-Induced Exacerbations

Medications that trigger or worsen psoriasis: 1

• β-blockers
• Lithium
• Antimalarials
• NSAIDs
• Tetracyclines

Biologic Safety Monitoring

Mandatory screening before initiating biologics: 1

• Tuberculosis testing
• Hepatitis B and C screening
• Complete blood count
• Liver function tests

Ongoing monitoring for:

• Serious infections 1
• Tuberculosis reactivation 1
• Lymphoma and other malignancies 1

Treatment Failure Algorithm

If inadequate response to first TNF inhibitor: Switch to another TNF inhibitor or change to different mechanism (IL-17 or IL-23 inhibitor). 6

When adjusting therapy: Consider disease activity, comorbidities, and safety issues simultaneously. 6